Locum Associate or Senior Editor, Nature Cancer – Berlin, Heidelberg or London – Hybrid working model
The Associate or Senior Editor will contribute to shaping the future of Nature Cancer journal.
The Associate or Senior Editor will contribute to shaping the future of Nature Cancer journal.
Ying Liu, MD, MPH, and Tiffany Sia, MD, discuss the benefits of mainstreaming genetic testing in patients with ovarian cancer.
The Video Journal of Hematological Oncology (VJHemOnc) is a global, open-access video journal, dedicated to providing trusted and up-to-date medical information in order to improve…
Key Points. High-dose alemtuzumab led to effective suppression of chronic GVHD.Lymphodepletion delays Tn recovery resulting in lower TCR repertoire and hig
Nature Communications – CAR T cell immunotherapy for paediatric solid and brain tumours is constrained by the availability of targetable antigens. Here, the authors investigate…
MRI-guided treatment could be used to optimize the duration of neoadjuvant chemotherapy in hormone receptor-negative/HER2-positive breast cancer.
We are delighted to announce EORTC’s participation at the ESTRO Congress 2024 taking place from 3 to 7 May 2024 in Glasgow, UK.
Sara Corvigno, MD, PhD, expands on an analysis that uncovered the CHIP variants that occurred at a higher frequency in patients with ovarian cancer post-chemotherapy.
Rohan Garje, MD, highlights advances made in precision medicine approaches for the management of metastatic prostate cancer.
Kara N. Maxwell, MD, PhD, discusses the prevalence of germline mutations in racially diverse cohorts of patients with metastatic prostate cancer.
This segment covers the diagnosis and initial treatment of a case of severe, multi-organ cGvHD, including the use of high-dose corticosteroids and other systemic agents.